<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC2017-2018_S08_ch08_p173-204</title>
		<link href="BCSC2017-2018_S08_ch08_p173-204-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC2017-2018_S08_ch08_p173-204" lang="en-US">
		<div id="_idContainer000" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter </span>8</p>
			<p class="chapter-title">Systemic Disorders With Corneal and Other Anterior Segment Manifestations</p>
			<p class="h1 ParaOverride-1">Highlights</p>
			 <div id="Chapt8_Top1">
			 <p class="body-text--no-indent-">
			<ul>
				<li class="bullet-list-mid">A Kayser-&#173;Fleischer ring is found not only in Wilson disease but also in primary biliary cirrhosis, chronic active hepatitis, and exogenous chalcosis. It should not be confused with a Fleischer ring, an iron ring seen in keratoconus.</li>
				<li class="bullet-list-mid">Crystals in the cornea are often related to amyloid deposition but may also be related to cystinosis and dysproteinemia.</li>
				<li class="bullet-list-mid">Patients with diabetes mellitus may have problems with epithelial healing after debridement and are at risk for recurrent corneal erosion.</li>
				<li class="bullet-list-mid">The differential diagnosis for prominent corneal nerves includes multiple endocrine neoplasia.</li>
			</ul>
			</p>
			</div>
			<p class="h1 ParaOverride-2">Introduction</p>
			 <div id="Chapt8_Top2">
			<p class="body-text--no-indent-">Corneal clarity can be affected by the accumulation of a variety of substances, such as carbohydrates, lipids, and amino or nucleic acids. The anterior segment can be affected by autoimmune, dermatologic, musculoskeletal, and other disease processes. Recognition of the manifestations of these disorders requires prompt medical intervention. This chapter reviews common systemic conditions affecting the anterior segment, particularly the cornea. See also BCSC Section&#160;2, <span class="italic">Fundamentals and Principles of Ophthalmology,</span> and Section&#160;6, <span class="italic">Pediatric Ophthalmology and Strabismus.</span></p>
			<p class="reference-first">Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017.</p>
			<p class="reference-last--no-space-">Poll-The BT, Maillette de Buy Wenniger-&#173;Prick CJ. The eye in metabolic disease: clues to diagnosis. <span class="italic">Eur&#160;J Paediatr Neurol.</span> 2011;15(3):197–204.</p>
			</div>
			<p class="h1">Inherited Metabolic Diseases</p>
			 <div id="Chapt8_Top3">
			<p class="h2-h1">Lysosomal Storage Diseases</p>
			<p class="body-text--no-indent-">Lysosomes are cellular organelles containing acid hydrolase enzymes that break down waste materials and cellular debris, including proteins, carbohydrates, lipids, and nucleic acids. Mutations in the genes that synthesize the lysosomal enzymes are responsible for more than 30&#160;different human genetic diseases, collectively known as lysosomal storage diseases. Each of these disorders is due to deficiency of a single lysosomal enzyme that prevents breakdown of target molecules.</p>
			<p class="h3">Systemic mucopolysaccharidoses</p>
			<p class="body-text--no-indent-">Systemic mucopolysaccharidoses (MPSs) are rare, inherited lysosomal storage diseases that can cause corneal clouding as a result of the accumulation of incompletely degraded glycosaminoglycans (GAGs; previously called mucopolysaccharides) within the keratocytes, corneal epithelium, and endothelium, as well as within the extracellular matrix of the cornea. These disorders result from defects in various lysosomal enzymes and are associated with other ophthalmic and systemic manifestations (<span class="xref-table">Table&#160;8-1</span>). The incidence of the MPSs is approximately 1 in 10,000&#160;births.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> At least 8&#160;MPS syndromes have been described, most of which are autosomal recessive. The exception is Hunter syndrome, which is X-linked recessive. Specific enzyme defects and genetic mutations have been identified for each of these syndromes. There is variation in phenotypic expression. For example, the three MPS&#160;I disorders (Hurler, Scheie, and Hurler-Scheie syndromes) arise from different amino acid substitutions that result in a deficiency of <span class="greek--tx-">a</span>-<span class="small-cap">l</span>-iduronidase. Hurler-&#173;Scheie is thought to result from the transmission of 1&#160;Hurler gene and 1&#160;Scheie gene.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Hurler syndrome (also termed MPS IH, MPS 1-H) is the most serious of the three MPS I disorders, with severe cognitive impairment and with corneal clouding appearing by 1&#160;year of age (<span class="xref-figure">Fig&#160;8-1</span>). The life span of patients with Hurler syndrome is very limited unless a bone marrow transplant is performed. In contrast, symptoms of Scheie syndrome (also called MPS&#160;IS, MPS&#160;1-S) do not appear until age 5–15&#160;years. As in Hurler syndrome, corneal clouding occurs in Scheie syndrome, but children with Scheie syndrome generally have normal intelligence and a normal life span. Hurler-&#173;Scheie syndrome (MPS IH/S) is an intermediate form. Ophthalmic manifestations of most MPSs include not only corneal clouding, but also retinopathy and optic atrophy. The clouding generally involves the entire cornea and may or may not be present at birth. It is often slowly progressive from the periphery toward the center and can cause serious reduction in vision.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> Urine can be screened for the presence of GAGs, but the most precise method of diagnosing the various MPSs is through a leukocyte or plasma enzyme assay. Confirmation of the disease can also be demonstrated using a conjunctival biopsy, although this is rarely necessary.</p>
			<p class="h5-text"><span class="h5-head">management</span> Penetrating keratoplasty (PK) or deep anterior lamellar keratoplasty (DALK) may be considered in the management of corneal clouding in the MPSs, although the patient’s mental status or retinal or optic nerve abnormalities may limit visual improvement. The visual prognosis for patients with MPS who have undergone PK is considered guarded, as the abnormal storage material may accumulate in the graft. Some regression of corneal clouding occurs in approximately one-third of patients following successful allogeneic bone marrow transplant. Enzyme replacement therapy is being used for several MPSs, and gene transfer therapy is under investigation.</p>
			<p class="reference-single--no-space- ParaOverride-3">Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. <span class="italic">Surv Oph</span><span class="italic">thalmol.</span> 2006;51(1):1–17.</p>
			<p class="h3 ParaOverride-4">Sphingolipidoses</p>
			<p class="body-text--no-indent-">Sphingolipidoses are rare inherited disorders of complex lipids (gangliosides and sphingomyelin) that involve the cornea. They comprise 4&#160;conditions:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-5">Fabry disease (angiokeratoma corporis diffusum), X-linked recessive</li>
				<li class="bullet-list-mid">multiple sulfatase deficiency, autosomal recessive</li>
				<li class="bullet-list-mid">generalized gangliosidosis (GM<span class="subscript _idGenCharOverride-1">1</span> gangliosidosis type&#160;I), autosomal recessive</li>
				<li class="bullet-list-nosp">Tay-Sachs disease (GM<span class="subscript _idGenCharOverride-1">2</span> gangliosidosis), autosomal recessive</li>
			</ul>
			<p class="h5-text ParaOverride-6"><span class="h5-head">pathogenesis</span> Fabry disease is caused by a deficiency of <span class="greek--tx-">a</span>-galactosidase&#160;A, which leads to the accumulation of ceramide trihexoside in the renal and cardiovascular systems. Generalized gangliosidosis is characterized by deficiencies of <span class="greek--tx-">b</span>-galactosidases and the resultant accumulation of ganglioside GM<span class="subscript _idGenCharOverride-1">1</span> in the central nervous system and of keratan sulfate in somatic tissues. It has been linked to 3p12–p13. Tay-Sachs disease is related to the generalized gangliosidoses but results from <span class="greek--tx-">b-</span>hexosaminidase A deficiency, which causes accumulation of ganglioside GM<span class="subscript _idGenCharOverride-1">2</span>.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">clinical presentation</span> In the sphingolipidoses, the cornea exhibits distinctive changes consisting of whorl-like lines <span class="italic">(cornea verticillata)</span> in the basal layers of the epithelium that appear to converge at the inferior central corneal epithelium (<span class="xref-figure">Fig&#160;8-2</span>).</p>
			<p class="body-text">Periorbital edema occurs in 25% of cases, posterior spokelike cataracts in 50%, and conjunctival aneurysms in 60%. Other ocular signs include papilledema, retinal or macular edema, optic atrophy, and retinal vascular dilation. The corneal changes resemble those noted in patients after long-term oral chloroquine or amiodarone therapy.</p>
			<p class="body-text">Hemizygous males with Fabry disease are more seriously affected than heterozygous females and show the typical corneal changes. A heterozygous female patient with Fabry disease will show the same corneal changes. Fabry disease is also characterized by renal failure, peripheral neuropathy with painful dysesthesias in the lower extremities, and skin lesions (angiokeratomas). The skin lesions are small, round, vascular eruptions that later become hyperkeratotic. They consist of an accumulation of sphingolipid within the vascular endothelium.</p>
			<p class="body-text">The clinical phenotype of multiple sulfatase deficiency combines features of metachromatic leukodystrophy and MPS. Affected children have subtle diffuse corneal opacities, macular changes, optic atrophy, and progressive psychomotor retardation. They die in the first decade of life.</p>
			<p class="body-text">The ocular findings in Tay-Sachs disease primarily involve the retina; however, the corneal endothelial cells can appear distended and filled with single membrane–bound vacuoles.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> In patients with Fabry disease, levels of <span class="greek--tx-">a-</span>galactosidase A are markedly decreased in urine and plasma. The conjunctival biopsy result may be positive before cornea verticillata are apparent. Prenatal diagnosis can be performed with chorionic villus sampling. Gene sequencing may help in diagnosing Fabry disease in suspected female carriers, as enzyme levels may be close to normal in heterozygotes.</p>
			<p class="h5-text"><span class="h5-head">management</span> If a female patient is found to be an asymptomatic heterozygous carrier of Fabry disease, genetic counseling should be considered. Enzyme replacement with infusion of <span class="greek--tx-">a-</span>galactosidase&#160;A is a therapeutic option, but long-term benefit has not been proven. Corneal deposits have been cleared with enzyme replacement therapy. The addition of agents that help stabilize native enzymes may improve the efficacy of enzyme replacement therapy.</p>
			<p class="reference-first ParaOverride-3">Fledelius HC, Sandfeld L, Rasmussen ÅK, Madsen CV, Feldt-&#173;Rasmussen U. Ophthalmic experience over 10&#160;years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement. <span class="italic">Acta Ophthalmol.</span> 2015;93(3):258–264.</p>
			<p class="reference-last--no-space-">Samiy N. Ocular features of Fabry disease: diagnosis of a treatable life-&#173;threatening disorder. <span class="italic">Surv Ophthalmol.</span> 2008;53(4):416–423.</p>
			<p class="h3 ParaOverride-7">Mucolipidoses</p>
			<p class="body-text--no-indent-">Mucolipidoses (MLs) are autosomal recessive conditions that have features common to both MPSs and lipidoses. Currently recognized diseases in this class are the following:</p>
			<ul>
				<li class="bullet-list-first">ML I (dysmorphic sialidosis)</li>
				<li class="bullet-list-mid">ML II (inclusion cell disease)</li>
				<li class="bullet-list-mid">ML III (pseudo-Hurler polydystrophy)</li>
				<li class="bullet-list-last">ML IV</li>
			</ul>
			<p class="body-text--no-indent-">See BCSC Section&#160;6, <span class="italic">Pediatric Ophthalmology and Strabismus,</span> and Section&#160;12, <span class="italic">Retina and Vitreous,</span> for additional discussion.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> The MLs are inherited disorders of carbohydrate and lipid metabolism combined. Incompletely degraded GAGs (mucopolysaccharides) accumulate in the cornea and viscera, and sphingolipids are deposited in the retina and central nervous system.</p>
			<p class="body-text">The ML IV gene has been mapped to the short arm of chromosome&#160;19. Histologic examination of corneal scrapings has revealed the accumulation of intracytoplasmic storage material in the corneal epithelium. All are caused by a defect in lysosomal acid hydrolase enzymes.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> All of the MLs are characterized by varying degrees of corneal clouding, which is often progressive. A retinal cherry-&#173;red spot and retinal degeneration are also associated with many of these disorders.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> Plasma cells are vacuolated, and levels of plasma lysosomal hydrolases are elevated. In ML&#160;IV, in which corneal clouding is present from birth, conjunctival biopsy shows fibroblast inclusion bodies that are</p>
			<ul>
				<li class="bullet-list-first">single membrane–limited cytoplasmic vacuoles containing both fibrillogranular material and membranous lamellae</li>
				<li class="bullet-list-last">lamellar and concentric bodies resembling those of Tay-Sachs disease</li>
			</ul>
			<p class="body-text--no-indent-">There is no evidence of mucopolysacchariduria or cellular metachromasia. Chorionic villus sampling has been used for prenatal diagnosis of ML&#160;II.</p>
			<p class="h5-text"><span class="h5-head">management</span> Both PK and lamellar keratoplasty (LK) have been associated with generally poor results, probably because resurfacing is impaired by the abnormal epithelial cells. Allograft limbal stem cell transplantation may be an option. Bone marrow transplantation has been reported.</p>
			<p class="h3">Miscellaneous lysosomal storage diseases</p>
			<p class="body-text--no-indent-">A number of the lysosomal storage diseases do not fit into a specific category. These include</p>
			<ul>
				<li class="bullet-list-first">galactosialidosis (Goldberg syndrome)</li>
				<li class="bullet-list-mid">mannosidosis</li>
				<li class="bullet-list-last">fucosidosis</li>
			</ul>
			<p class="body-text--no-indent-">Goldberg syndrome is a cathepsin-&#173;related disorder and has features of <span class="greek--tx-">b-</span>galactosidase and sialidase deficiencies. Mannosidosis is caused by deficient activity of the enzyme mannosidase. There are 2&#160;subsets, <span class="greek--tx-">a-</span> and <span class="greek--tx-">b-</span>mannosidosis. Both galactosialidosis and mannosidosis are associated with corneal clouding.</p>
			<p class="body-text">Fucosidosis is due to mutations in the <span class="italic">FUCA1</span> gene, which result in reduction in activity of the <span class="greek--tx-">a-</span><span class="small-cap">l</span>-fucosidase enzyme. Histologic studies have revealed that even when the cornea appears clinically normal in fucosidosis, corneal endothelial cells show the presence of cytoplasmic, membrane-&#173;bound, confluent areas of fibrillar, granular, and multilaminated deposits.</p>
			<p class="h2 ParaOverride-8">Disorders of Lipoprotein Metabolism</p>
			<p class="h3-h2">Hyperlipoproteinemias</p>
			<p class="body-text--no-indent-">Hyperlipoproteinemias are common conditions associated with premature coronary artery and peripheral vascular disease. Recognition of the ocular hallmarks of these diseases, such as xanthelasma and corneal arcus, can result in early intervention and reduced morbidity.</p>
			<p class="body-text">Schnyder corneal dystrophy, a dominantly inherited category&#160;1 corneal dystrophy, can be associated with hyperlipoproteinemia. Corneal dystrophies are discussed in Chapter&#160;7.</p>
			<p class="body-text">See BCSC Section&#160;1, <span class="italic">Update on General Medicine,</span> for additional information about hyperlipoproteinemias.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> Extracellular deposits consist of cholesterol, cholesterol esters, phospholipids, and triglycerides.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Corneal arcus is a very common degenerative change in older patients and does not require systemic evaluation (see Chapter&#160;6 for further discussion of corneal arcus). However, corneal arcus in individuals younger than 40&#160;years or asymmetric corneal arcus may be associated with a hyperlipoproteinemia with elevated serum cholesterol level. These patients should have a systemic workup. Unilateral or asymmetric corneal arcus may be secondary to carotid atherosclerotic disease on the less affected side.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> A fasting and alcohol-&#173;restricted lipid profile that includes cholesterol, triglycerides, and high-&#173;density and low-&#173;density lipoproteins (HDL and LDL, respectively) is typically considered. The clinician can then classify these patients phenotypically to assess their risk for atherosclerotic disease.</p>
			<p class="h5-text"><span class="h5-head">management</span> Early detection of a hyperlipoproteinemia by the ophthalmologist allows time for the patient to be referred for dietary or drug treatment.</p>
			<p class="h3">Hypolipoproteinemias</p>
			<p class="body-text--no-indent-">Abnormal reductions in serum lipoprotein levels occur in 5&#160;disorders:</p>
			<ul>
				<li class="bullet-list-first">lecithin–cholesterol acyltransferase (LCAT) deficiency</li>
				<li class="bullet-list-mid">fish eye disease</li>
				<li class="bullet-list-mid">Tangier disease</li>
				<li class="bullet-list-mid">familial hypobetalipoproteinemia</li>
				<li class="bullet-list-last">Bassen-Kornzweig syndrome</li>
			</ul>
			<p class="body-text--no-indent-">The last 2&#160;disorders do not result in corneal disease; the discussion in this section focuses on the other 3&#160;disorders.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> LCAT promotes transfer of excess cholesterol from peripheral tissues to the liver, and a deficiency of this enzyme results in accumulation of unesterified cholesterol in the plasma and tissues. This, in turn, leads to atherosclerosis, renal insufficiency, early corneal arcus, and nebular corneal clouding composed of minute focal lipid deposits.</p>
			<p class="body-text">LCAT deficiency and fish eye disease are allelic variants of the same genetic locus on band 16q22.1. In fish eye disease, LCAT levels are normal, but the enzyme does not function properly. Tangier disease is characterized by a complete absence of serum high-&#173;density <span class="greek--tx-">a</span>-lipoproteins. The gene responsible for this disease maps to 9q22–q31.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> LCAT deficiency, fish eye disease, and Tangier disease are rare autosomal recessive conditions. Familial LCAT deficiency is characterized by peripheral arcus and nebular stromal haze made up of myriad minute focal deposits of lipid that appear early in childhood but do not interfere with vision (<span class="xref-figure">Fig&#160;8-3</span>). Fish eye disease features obvious corneal clouding from minute gray-white-&#173;yellow dots that progress from the periphery to the central cornea to decrease vision. Tangier disease features very large orange tonsils; enlarged liver, spleen, and lymph nodes; hypocholesterolemia; and abnormal chylomicron remnants. Affected corneas show diffuse clouding and posterior focal stromal opacities but no arcus. Neuropathy leads to lagophthalmos and corneal sequelae.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation and management</span> The serum lipid profile shows characteristic low levels of HDL (markedly low in Tangier disease). Recognition of hypolipoproteinemia can allow the clinician to make appropriate referrals and encourage the patient to seek genetic counseling.</p>
			<p class="h2 ParaOverride-7">Disorders of Amino Acid, Nucleic Acid, Protein, and Mineral Metabolism</p>
			<p class="h3-h2">Cystinosis</p>
			<p class="body-text--no-indent-">Cystinosis is a rare autosomal recessive metabolic disorder, affecting 3.5&#160;infants per 1&#160;million births. The disease is characterized by the accumulation of the amino acid cystine within lysosomes. The defective gene in cystinosis, <span class="italic">CTNS,</span> has been mapped to 17p13. See also BCSC Section&#160;6, <span class="italic">Pediatric Ophthalmology and Strabismus.</span></p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> A defect in transport across the lysosomal membrane leads to intracellular accumulation of cystine.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Cystinosis is categorized on the basis of the patient’s age at diagnosis and the severity of symptoms. <span class="italic">Nephropathic cystinosis</span> is divided into infantile (classic) and intermediate (juvenile or adolescent) forms. Dwarfism and progressive renal dysfunction are prominent in infantile cystinosis and less severe in the juvenile disease. Life expectancy is normal in <span class="italic">nonnephropathic cystinosis</span> (formerly called <span class="italic">adult cystinosis</span>). All 3&#160;types are characterized by the deposition of fine iridescent and polychromatic cystine crystals in the conjunctiva, cornea, iris, and other parts of the eye. The crystals are densest in the peripheral cornea but are present throughout the anterior stroma, even within the central cornea (<span class="xref-figure">Fig&#160;8-4</span>), and can be seen in the trabecular meshwork with gonioscopy. Patients with cystinosis often have photophobia, and the crystals can recur following PK. <span class="xref-table">Table&#160;8-2</span> lists other causes of corneal crystals; <span class="xref-table">Table&#160;8-3</span> summarizes the ocular and systemic findings in disorders of amino acid metabolism.</p>
			<p class="reference-single--no-space- ParaOverride-6">Liang H, Baudouin C, Tahiri JHR, Brignole-Baudouin F, Labbe A. Photophobia and corneal crystal density in nephropathic cystinosis: an in vivo confocal microscopy and anterior segment optical coherence tomography study. <span class="italic">Invest Ophthalmol Vis Sci.</span> 2015;56(5):<br />3218–3225.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">laboratory evaluation</span> Cystine crystals may be seen in conjunctiva, blood leukocytes, or bone marrow.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">management</span> Topical cysteamine 0.44% is a commercially available agent used to reduce the density of the crystals and diminish corneal pain, possibly by reducing the frequency of corneal erosions. Cysteamine is thought to react with intracellular cystine, forming a cysteine–cysteamine disulfide that resembles lysine and is transported through the lysosome by the normal lysine transport system. Posterior segment manifestations such as pigmentary retinopathy and optic nerve involvement may be treated with oral cysteamine, which may also prevent or delay other manifestations of the disease, including death.</p>
			<p class="h3">Tyrosinemia</p>
			<p class="body-text--no-indent-">Tyrosinemia encompasses a group of inborn errors in the metabolism of the amino acid tyrosine. Tyrosinemia type&#160;I, caused by fumarylacetoacetate deficiency, is not associated with corneal pathology. Tyrosinemia type&#160;II (Richner-&#173;Hanhart syndrome) is characterized by hyperkeratotic lesions of the palms, soles, and elbows, as well as eventual cognitive impairment; corneal manifestations of this syndrome are discussed under Clinical Presentation.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">pathogenesis</span> Tyrosinemia type&#160;II is an autosomal recessive disorder resulting from defective tyrosine aminotransferase, which leads to excess tyrosine in the blood and urine. The elevated tyrosine level likely has a direct effect on lysosomal membranes, leading to enzyme release. The gene defect is located at 16q22.1–22.3.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">clinical presentation</span> Ocular changes include marked photophobia, tearing, conjunctival injection, and tarsal papillary hypertrophy. Affected patients experience recurrent episodes of corneal erosions and pseudodendrites (<span class="xref-figure">Fig&#160;8-5</span>), which usually do not stain well with fluorescein or rose bengal. Continued episodes of epithelial breakdown can result in corneal vascularization and scarring. It is important to consider this disorder in young children who may carry a diagnosis of recurrent herpes simplex virus keratitis.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">laboratory evaluation</span> Hypertyrosinemia and tyrosinuria with normal phenylalanine levels and conjunctival biopsy showing soluble tyrosine aminotransferase deficiency are diagnostic.</p>
			<p class="h5-text"><span class="h5-head">management</span> Restriction of dietary intake of tyrosine and phenylalanine can reduce the severity of both the corneal and systemic changes, including cognitive impairment. The institution of appropriate dietary restrictions, even later in life, can improve mental status.</p>
			<p class="h3">Alkaptonuria</p>
			<p class="body-text--no-indent-">Alkaptonuria is a rare autosomal recessive disorder caused by deficiency of the enzyme homogentisic acid oxidase, which leads to an accumulation of homogentisic acid. The defect is caused by mutations in the <span class="italic">HGD</span> gene, which maps to 3q13.33. The frequency of alkaptonuria is unusually high in the Dominican Republic and Slovakia.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> Homogentisate 1,2-dioxygenase, the enzyme necessary to degrade tyrosine and phenylalanine, is deficient in patients with this disorder. Phenylalanine and tyrosine cannot be metabolized beyond homogentisic acid, which is oxidized and poly&#173;merized into alkapton, a brown-black material similar to melanin. Alkapton binds to collagen and is then deposited in connective tissues as a dark pigment; this process is known as <span class="italic">ochronosis.</span></p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Systemic findings include arthropathy; renal calculi; and pigmentation of cartilaginous structures, including earlobes, trachea, nose, tendons, dura mater, heart valves, and prostate. Eventually, medial and lateral rectus muscle tendons and the sclera adjacent to the tendon insertions develop a smudgelike bluish-black pigmentation (<span class="xref-figure">Fig&#160;8-6</span>). Darkly pigmented, dotlike opacities, similar to those seen in spheroidal degeneration, may appear in the corneal epithelium or in the Bowman layer, near the limbus.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> The urine of affected patients turns dark on standing. Alkaptonuria is diagnosed by finding elevated levels of homogentisic acid in the urine.</p>
			<p class="h5-text"><span class="h5-head">management</span> No specific therapy is available, but high-dose ascorbic acid may reduce arthropathy in young patients. Gene therapy may be a future treatment.</p>
			<p class="reference-single--no-space- ParaOverride-9">Srinivasan S, Shehadeh-&#173;Mashor R, Slomovic AR. Corneal manifestations of metabolic diseases. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:620–644.</p>
			<p class="h3">Amyloidosis</p>
			<p class="body-text--no-indent-">The amyloidoses are a heterogeneous group of diseases characterized by the extracellular accumulation of amyloid in various tissues and organs, including the cornea and conjunctiva. Amyloid deposits may be composed of many different types of proteins, including immunoglobulin fragments. The deposits are insoluble and inert, but they interfere with the normal structure and function of tissues and organs.</p>
			<p class="body-text">Amyloid has the following staining characteristics:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-10">positive staining with Congo red dye</li>
				<li class="bullet-list-mid">dichroism and birefringence</li>
				<li class="bullet-list-mid">metachromasia with crystal violet dye</li>
				<li class="bullet-list-mid">fluorescence in ultraviolet light with thioflavin T stain</li>
				<li class="bullet-list-last ParaOverride-11">typical filamentous appearance on electron microscopy</li>
			</ul>
			<p class="h5-text"><span class="h5-head">classification and clinical presentation</span> Ocular amyloidosis is classified as either primary (idiopathic) or secondary (to a chronic disease) and as either localized or systemic. A useful classification of amyloidosis considers these 4&#160;types. Each type is summarized in <span class="xref-table">Table&#160;8-4</span>.</p>
			<p class="body-text"><span class="italic">Primary localized amyloidosis</span> is the most common form of ocular amyloidosis. Conjunctival amyloid plaques occur in the absence of systemic involvement (<span class="xref-figure">Fig&#160;8-7</span>). Gelatinous droplike corneal dystrophy (formerly primary familial amyloidosis), classic lattice corneal dystrophy (LCD1), and lattice variants are special forms of primary localized amyloidosis and are discussed in Chapter&#160;7. Polymorphic amyloid degeneration is discussed in Chapter&#160;6.</p>
			<p class="body-text"><span class="italic">Primary systemic amyloidosis</span> is a heterogeneous group of diseases in which waxy, ecchymotic eyelid papules occur in association with vitreous veils and opacities as well as with pupillary anomalies such as light–near dissociation. Orbital involvement, extraocular muscle involvement with ophthalmoplegia, and scleral infiltration with uveal effusion have been reported. The most common form of primary systemic amyloidosis is an autosomal dominant group of diseases linked to mutations in the transthyretin gene (<span class="italic">TTR,</span> prealbumin) on chromosome&#160;18 (18q11.2–q12.1); more than 40&#160;mutations in this gene have been described.</p>
			<p class="body-text"><span class="italic">Familial amyloidosis, Finnish type, </span><span class="italic CharOverride-1">or</span><span class="italic"> gelsolin type (Meretoja syndrome)</span> is an example of primary systemic amyloidosis. This condition was initially described in persons of Finnish descent but was later reported in individuals of other ethnicities. Previously called lattice corneal dystrophy type&#160;2, it has been excluded as a corneal dystrophy by the International Committee for the Classification of Corneal Dystrophies (IC3D) because of its systemic associations.</p>
			<p class="body-text">Familial amyloidosis presents in the third to fourth decade of life. Because the ocular symptoms are the first to arise, the ophthalmologist is often the first physician to see patients with this condition, who typically present with corneal findings. Affected patients have a characteristic facial mask; dermatochalasis; lagophthalmos; pendulous ears; cranial and peripheral nerve palsies; and dry, lax skin with amyloid deposition (<span class="xref-figure">Fig&#160;8-8</span>). The classic corneal lattice lines are less numerous and more peripheral, and they spread centripetally from the limbus. The central cornea is relatively spared; corneal sensation is reduced. The risk of open-&#173;angle glaucoma may be increased, and dry eye and recurrent erosions may occur late in life.</p>
			<p class="h5-text"><span class="h5-head">pathology of familial amyloidosis</span> Light microscopy shows amyloid in the lattice lines as a discontinuous band under the Bowman layer and within the sclera. The amyloid in this condition is related to gelsolin and does not stain for type&#160;AA or AP. The mutated gelsolin is observed to be deposited in the conjunctiva, sclera, and ciliary body; along the choriocapillaris; in the ciliary nerves and vessels; and in the optic nerve. Extraocularly, amyloid is detected in arterial walls, peripheral nerves, and glomeruli. On confocal microscopy, deposits are observed along the basal epithelial cells and stromal nerves.</p>
			<p class="reference-first ParaOverride-3">Reidy JJ. Corneal and conjunctival degenerations. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:856–874.</p>
			<p class="reference-last--no-space-">Srinivasan S, Shehadeh-Mashor R, Slomovic AR. Corneal manifestations of metabolic diseases. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:<br />620–644.</p>
			<p class="h3">Gout</p>
			<p class="body-text--no-indent-">Disorders of purine metabolism cause <span class="italic">hyperuricemia</span> (increased uric acid). <span class="italic">Gout</span> results from deposition of urate crystals in the joints or kidney.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> Hyperuricemia may be familial, arising from an enzyme deficiency (eg, hypoxanthine phosphoribosyltransferase in Lesch-Nyhan syndrome). More commonly, gout is polygenic or secondary to obesity, cytotoxic chemotherapy, myeloproliferative disease, diuretic therapy, or excessive alcohol consumption.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Acute inflammation of the sclera, episclera, or conjunctiva can occur. Fine corneal epithelial and stromal deposits may appear in the absence of inflammation. Either an orange-brown band keratopathy or a typical whitish band keratopathy is seen in rare cases.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> Serum uric acid level is typically elevated. However, in urate keratopathy, the uric acid level may be normal in the presence of keratopathy if there is no concurrent inflammation.</p>
			<p class="h5-text"><span class="h5-head">management</span> Indomethacin, colchicine, or phenylbutazone is used for acute treatment; long-term reduction in uric acid levels should be pursued with medications such as allopurinol. Superficial corneal deposits can be removed mechanically with scraping or keratectomy.</p>
			<p class="h3">Wilson disease</p>
			<p class="h5-text ParaOverride-1"><span class="h5-head">pathogenesis</span> Wilson disease <span class="italic">(hepatolenticular degeneration)</span> is an autosomal recessive disorder caused by multiple allelic substitutions or deletions in a Cu<span class="superscript CharOverride-2">2+</span>-ATPase-transporting <span class="greek--tx-">b-</span>polypeptide, linked to mutations in the <span class="italic">ATP7B</span> gene on chromosome&#160;13 (13q14.3–q21). Copper is deposited first in the liver, then in the kidneys, and eventually in the brain and the cornea at the Descemet membrane (<span class="xref-figure">Fig&#160;8-9</span>).</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Muscular rigidity increases, and tremor and involuntary movement gradually occur in a fluctuating course resembling parkinsonism. Unintelligible speech and mild dementia usually occur concomitantly. Equal numbers of patients (40%) present with hepatic or nervous system symptoms. In the cornea, a golden-&#173;brown, ruby-red, or green pigment ring (Kayser-&#173;Fleischer ring) consisting of copper deposits appears in peripheral Descemet membrane (see Fig&#160;8-9), although not all patients with Wilson disease manifest this ring. Copper deposition occurs in the posterior Descemet membrane, first superiorly, then gradually spreading to meet inferior deposits. Gonioscopy may assist in visualizing the ring. A “sunflower” cataract may be present.</p>
			<p class="body-text">The differential diagnosis includes primary biliary cirrhosis, chronic active hepatitis, exogenous chalcosis, and progressive intrahepatic cholestasis of childhood. These and other non-&#173;Wilsonian hepatic disorders can also be associated with Kayser-&#173;Fleischer rings, but only Wilson disease is characterized by decreased serum ceruloplasmin levels and neurologic symptoms.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> Patients with Wilson disease can be differentiated from patients with other diseases that show Kayser-&#173;Fleischer rings by their inability to incorporate radioactive copper into ceruloplasmin. Low serum ceruloplasmin, high non-&#173;ceruloplasmin-bound serum copper, and high urinary copper suggest the diagnosis, which can be confirmed with liver biopsy. Nonspecific findings of proteinuria, aminoaciduria, glycosuria, uricaciduria, hyperphosphaturia, and hypercalciuria are seen.</p>
			<p class="h5-text"><span class="h5-head">management</span> Wilson disease can be treated with penicillamine. Liver transplantation is reserved for patients with fulminant liver failure. The Kayser-&#173;Fleischer ring disappears gradually with therapy, including liver transplant, and the disappearance of the rings can be used to help monitor therapy. Electrophysiologic abnormalities from retinal dysfunction have been shown to reverse after treatment of the disease.</p>
			<p class="h3">Porphyria</p>
			<p class="body-text--no-indent-">The porphyrias are a group of disorders characterized by excess production and excretion of porphyrins, which are pigments involved in the synthesis of heme.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> <span class="italic">Porphyria cutanea tarda,</span> the form most commonly associated with ocular surface disease, is either sporadic or inherited in an autosomal dominant pattern (band 1p34). The enzyme uroporphyrinogen decarboxylase is deficient, resulting in an accumulation of porphyrins in the liver and in the circulation. Typically, a second insult to the liver, such as alcoholism or drug metabolism, triggers the condition in late middle age.</p>
			<p class="body-text">A severe form of porphyria, called <span class="italic">hepatoerythropoietic porphyria (HEP),</span> is a homozygous presentation of the same enzymatic defect, but onset of the disease is in infancy.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Hyperpigmentation, erythema, scleroderma-&#173;like changes, increased fragility, and vesicular and ulcerative lesions occur on sun-&#173;exposed surfaces of the body. There is interpalpebral injection, and the conjunctiva may develop vesicles, scarring, and symblepharon mimicking bullous pemphigoid; conjunctival necrosis may also occur. Necrotizing scleritis has been reported. The cornea may be affected by exposure or by thinning and perforation at the limbus. Skin and ocular lesions may fluoresce.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> Urine turns dark on standing. Reduced liver and red cell uroporphyrinogen decarboxylase activity confirms the diagnosis. Hepatic biopsy shows liver parenchymal cells filled with porphyrins that fluoresce bright red in ultraviolet light.</p>
			<p class="h5-text"><span class="h5-head">management</span> Protection from ultraviolet light and reduction of iron by phlebotomy or subcutaneous deferoxamine are the principal treatments. No specific ocular treatment is available, although artificial tears may help wash away porphyrins. Corneal thinning and perforation are treated in standard ways.</p>
			<p class="reference-single--no-space-">Srinivasan S, Shehadeh-Mashor R, Slomovic AR. Corneal manifestations of metabolic diseases. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:620–644.</p>
			</div>
			<p class="h1 ParaOverride-12">Skeletal and Connective Tissue Disorders</p>
			 <div id="Chapt8_Top4">
			<p class="body-text--no-indent-">Many musculoskeletal and connective tissue diseases affect the cornea. The corneal manifestations of these diseases are outlined in <span class="xref-table">Table&#160;8-5</span>.</p>
			<p class="h2">Ehlers-Danlos Syndrome</p>
			<p class="body-text--no-indent-">Ehlers-Danlos syndrome (EDS), a heterogeneous group of diseases, is characterized by hyperextensibility of joints and skin, tendency to bruise easily, and formation of “cigarette paper” scars.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> There are more than 20&#160;known types of EDS, which are classified as autosomal dominant, autosomal recessive, or X-linked recessive. Multiple genetic loci have been identified. Specific defects occur in collagen type&#160;I and III synthesis; lysyl hydroxylase deficiency may occur as well.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Ehlers-Danlos syndrome type&#160;VI (EDS&#160;VI), or the ocular–scoliotic type, is autosomal recessive and associated with only moderate joint and skin extensibility, brittle cornea easily ruptured upon minor trauma, blue sclera, keratoconus and keratoglobus, and severe scoliosis. Type&#160;VIA shows lysyl hydroxylase deficiency, but type&#160;VIB shows normal production of lysyl hydroxylase.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> Traditionally, clinical diagnosis of EDS&#160;VI is confirmed by an insufficiency of hydroxylysine on analysis of hydrolyzed dermis and/or reduced enzyme activity in cultured skin fibroblasts. However, the diagnosis can also be confirmed by an altered urinary ratio of lysyl pyridinoline to hydroxylysyl pyridinoline, which is characteristic of EDS&#160;VI.</p>
			<p class="h5-text"><span class="h5-head">management</span> Recognition of EDS VI is essential. In addition, the clinician must be aware of the syndrome’s association with mitral valve prolapse, spontaneous bowel rupture, and strabismus surgery complications, as well as the potential to confuse the brittle cornea with injury due to child abuse. Use of patch grafts for repair of corneoscleral ruptures has been successful. Genetic counseling should be considered.</p>
			<p class="h2">Marfan Syndrome</p>
			<p class="body-text--no-indent-">Marfan syndrome is a common autosomal dominant disorder associated with disorders of the eye (ectopia lentis) (<span class="xref-figure">Fig&#160;8-10</span>), heart (dilation of the aortic root and aneurysms of the aorta), and skeletal system (arachnodactyly, pectus excavatum, and kyphoscoliosis).</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> Fibrillin and glycoprotein make up the microfibrillar system of the extracellular matrix. Fibrillin is found in corneal basement membrane, zonular fibers of the lens and capsule, and sclera. The syndrome is caused by mutations in the <span class="italic">FBN1</span> gene, which encodes fibrillin-1 and maps to 15q21.1.</p>
			<p class="h5-text ParaOverride-3"><span class="h5-head">clinical presentation</span> Defects in fibrillin synthesis lead to thinning of the sclera (blue sclera), subluxation of the lens, and flattening of the cornea. Open-&#173;angle glaucoma and cataract occur at a higher rate and at an earlier age than in the population without Marfan syndrome. Megalocornea and keratoconus are uncommon, but excessive flattening, in the range of 35&#160;diopters&#160;(D), occurs in up to 20% of patients.</p>
			<p class="h5-text ParaOverride-3"><span class="h5-head">management</span> Cardiac evaluation is typically considered, given that premature mortality is associated with aortic complications. Treatment of lens subluxation may require the use of advanced cataract surgery techniques such as capsular tension rings or scleral fixation; in severe cases of subluxation, a pars plana approach may be a better way to safely remove the lens. BCSC Section&#160;11, <span class="italic">Lens and Cataract,</span> discusses the lens subluxation caused by Marfan syndrome and its treatment.</p>
			<p class="h2 ParaOverride-7">Osteogenesis Imperfecta</p>
			<p class="body-text--no-indent-">Osteogenesis imperfecta is a rare, dominantly inherited condition occurring in 1 in 20,000&#160;live births. There are 4&#160;types resulting from mutations in the <span class="italic">COL1A1</span> and <span class="italic">COL1A2</span> genes. The disease results in defects in the skeleton and teeth, hearing deficits, and ocular anomalies.</p>
			<p class="h5-text ParaOverride-3"><span class="h5-head">pathogenesis</span> The genetic mutation causes abnormalities of the <span class="greek--tx-">a</span>1 or <span class="greek--tx-">a</span>2 chain of type&#160;I collagen. As a result, the collagen fibrils fail to mature to their normal diameters.</p>
			<p class="h5-text ParaOverride-3"><span class="h5-head">clinical presentation</span> Patients with osteogenesis imperfecta are susceptible to brittle bones and multiple skeletal fractures. Hearing loss is common; the prevalence ranges from 50% to 92% in some studies. Hearing loss may be conductive, mixed, or sensorineural and is more common after adolescence. Patients are also predisposed to brittle teeth. Ocular manifestations include blue sclera (<span class="xref-figure">Fig&#160;8-11</span>) and reduced central corneal thickness (average of 450&#160;µm). The blue sclera is present throughout life in type&#160;I osteogenesis imperfecta, but fades within the first few years of life in the other 3&#160;types. Other rare ocular findings include optic nerve damage due to fractures in the calvarial bones, keratoconus, and megalocornea. <span class="xref-table">Table&#160;8-6</span> summarizes other conditions associated with blue sclera.</p>
			<p class="h5-text ParaOverride-3"><span class="h5-head">management</span> Treatment with oral bisphosphonates reduces bone resorption, and aggressive orthopedic management of fractures is indicated. Low-&#173;impact exercise might help preserve bone and muscle integrity.</p>
			<p class="h2">Goldenhar-Gorlin Syndrome</p>
			<p class="body-text--no-indent-">Goldenhar-Gorlin syndrome, also known as <span class="italic">oculoauriculovertebral (OAV) syndrome,</span> is a rare congenital condition characterized by incomplete development of the ear, nose, soft palate, lip, and mandible. It is associated with anomalous development of the first branchial arch and second branchial arch.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">pathogenesis</span> The cause of Goldenhar-&#173;Gorlin syndrome is uncertain, but it may have a genetic component.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">clinical presentation</span> Common clinical manifestations include limbal dermoids (<span class="xref-figure">Fig&#160;8</span><span class="xref-figure">-</span><span class="xref-figure">12</span><span class="xref-figure">A</span>), preauricular skin tags (Fig&#160;8-12B), and strabismus. Affected patients also have hemifacial microsomia and hearing difficulties. The condition can be associated with colobomas of the eyelids (upper &gt; lower eyelid) and with aural fistulae. In addition, scoliosis can develop secondary to incomplete development of the vertebrae. Corneal dermoids can occur independently of Goldenhar-&#173;Gorlin syndrome and are choristomas that result from faulty development of eyelid folds; thus, they are displaced embryonic tissue that was destined to become skin. Dermoids are composed of fibrous and fatty tissue and occasionally hair and sebaceous gland material. Limbal dermoids are covered by conjunctiva and often have an arcuslike deposition of lipid along their anterior corneal border. See Table&#160;8-5 for additional clinical findings.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">management</span> Corneal dermoids can lead to amblyopia if they induce significant corneal astigmatism. As the child grows, the dermoid enlarges with the eye; it has virtually no malignant potential. The elevated portion of the dermoids can be surgically shaved down to improve cosmetic appearance, but the lesions often extend deep into underlying tissues. Some corneal astigmatism might remain, but it can permit fitting of a rigid contact lens. LK can also improve the cosmetic appearance.</p>
			<p class="reference-single--no-space-">Al-Shamekh S, Traboulsi EI. Skeletal and connective tissue disorders with anterior segment manifestations. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:645–664.</p>
			</div>
			<p class="h1">Nutritional Disorder: Vitamin A Deficiency</p>
			 <div id="Chapt8_Top5">
			<p class="body-text--no-indent-">Vitamin A deficiency is a leading cause of blindness in developing countries and is responsible for at least 20,000–100,000&#160;new cases of blindness worldwide each year. The earliest manifestation of vision loss is night blindness, or nyctalopia. At greatest risk are malnourished infants and babies born to vitamin&#160;A–deficient mothers, especially infants who have another biological stressor, such as measles or diarrhea. Superficial concurrent infections due to herpes simplex virus, measles virus, or bacterial agents probably further predispose these children to keratomalacia and blindness. Although xerophthalmia usually results from low dietary intake of vitamin&#160;A, decreased absorption of vitamin&#160;A may also be responsible. In cases of vitamin&#160;A deficiency and xerophthalmia occurring in countries with a low rate of malnutrition, the condition is usually caused by unusual self-&#173;imposed dietary practices, chronic alcoholism, or lipid malabsorption (seen in cystic fibrosis, biliary cirrhosis, and bowel resection). The increase in gastric bypass surgical procedures may lead to an increased incidence of vitamin&#160;A deficiency.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">pathogenesis</span> Vitamin&#160;A deficiency causes blindness by inhibiting the production of rhodopsin. Xerosis (abnormal dryness) of the conjunctiva and cornea due to vitamin&#160;A deficiency is associated with loss of mucus production by the goblet cells. Similar changes can occur in epithelial cells of the gastrointestinal, genitourinary, and respiratory tracts.</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">clinical presentation</span> One ocular consequence is the Bitôt spot (<span class="xref-figure">Fig&#160;8-13</span>), a superficial foamy, gray, triangular lesion on the bulbar conjunctiva that appears in the palpebral aperture. This spot consists of keratinized epithelium, inflammatory cells, debris, and <span class="italic">Corynebacterium xerosis.</span> <span class="italic">Corynebacterium</span> bacilli metabolize the debris, producing the foamy appearance. Prolonged vitamin A deficiency may lead to corneal ulcers and scars and eventually cause diffuse corneal necrosis (keratomalacia). The World Health Organization classifies the ocular surface changes into 3&#160;stages:</p>
			<p class="numbered-list-first">&#9;1.&#9;conjunctival xerosis, without (X1A) or with (X1B) Bitôt spots</p>
			<p class="numbered-list-mid">&#9;2.&#9;corneal xerosis (X2)</p>
			<p class="numbered-list-mid">&#9;3.&#9;corneal ulceration, with keratomalacia involving less than one-third (X3A) or more than one-third (X3B) of the corneal surface</p>
			<p class="h5-text ParaOverride-6"><span class="h5-head">management</span> Systemic vitamin A deficiency, best characterized by keratomalacia, is a medical emergency with a mortality rate of 50% if untreated. Although the administration of oral vitamin A will address the acute manifestations of keratomalacia, patients with this condition are usually affected by much broader protein-&#173;energy malnutrition and should be treated with both vitamin and protein-&#173;calorie supplements. Malabsorption may render oral administration ineffective in patients with acute vitamin&#160;A deficiency. Maintenance of adequate corneal lubrication and prevention of secondary infection and corneal melting are essential steps in treating keratomalacia, but identification and proper treatment of the underlying causes are vital to successful clinical management of the ocular complications.</p>
			<p class="reference-first">Mannis T, Mannis MJ, Paranjpe DR, Kirkness CM. Nutritional disorders. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:676–687.</p>
			<p class="reference-last--no-space-">Sommer A. Vitamin A deficiency and clinical disease: an historical overview. <span class="italic">J&#160;Nutr.</span> 2008;<br />138(10):1835–1839.</p>
			</div>
			<p class="h1">Hematologic Disorders</p>
			 <div id="Chapt8_Top6">
			<p class="body-text--no-indent-">The excess synthesis of immunoglobulins by plasma cells in multiple myeloma, Waldenström macroglobulinemia, and benign monoclonal gammopathy may be associated with crystalline corneal deposits (<span class="xref-figure">Fig&#160;8-14</span>).</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> Monoclonal proliferation of plasma cells (B&#160;lymphocytes) leads to overproduction of both light (<span class="greek--tx-">j</span> or <span class="greek--tx-">k</span>) chains and heavy (<span class="greek--tx-">a</span>, <span class="greek--tx-">c</span>, <span class="greek--tx-">e</span>, <span class="greek--tx-">d</span>, or µ) chains (collectively termed M&#160;proteins), overproduction of light chains with or without production of heavy chains (Bence Jones protein), or overproduction of heavy chains without light chains (heavy-&#173;chain disease). Pathogenesis is related either to direct tissue invasion, particularly of the bone marrow, or to hyperviscosity syndrome. Secondary hypercalcemia may occur. Deposition of paraproteins in the cornea is very rare and is related to diffusion of the proteins—probably from the limbal vessels or, alternatively, from the tears or aqueous humor—followed by precipitation that may be related to corneal temperature or local tissue factors.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Ophthalmic findings may include the following:</p>
			<ul>
				<li class="bullet-list-first">crystalline deposition in all layers of the cornea or in the conjunctiva</li>
				<li class="bullet-list-mid">copper deposition in the cornea</li>
				<li class="bullet-list-mid">“sludging” of blood flow in the conjunctiva and retina</li>
				<li class="bullet-list-mid">pars plana proteinaceous cysts</li>
				<li class="bullet-list-mid">infiltration of the sclera</li>
				<li class="bullet-list-last">orbital bony invasion with proptosis</li>
			</ul>
			<p class="body-text--no-indent-">Corneal deposits are numerous, scintillating, and polychromatic. They are typical of immunoglobulin&#160;G <span class="greek--tx-">j-</span>chain deposition and may be related to the size of the paraprotein and the chronicity of the disease.</p>
			<p class="body-text"><span class="italic">Waldenström macroglobulinemia</span> is characterized by malignant proliferation of plasma cells generating immunoglobulin&#160;M, causing hyperviscosity syndrome, principally in older men. It has been associated with needlelike crystals and amorphous deposits subepithelially and in deep stroma (<span class="xref-figure">Fig&#160;8-15</span>).</p>
			<p class="body-text"><span class="italic">Benign monoclonal gammopathy</span> is a frequent (up to 6%) finding in individuals older than 60&#160;years. Results of the systemic evaluation in these cases are negative, but a mild increase in paraprotein (&lt;3&#160;g/dL) is detected. Slit-lamp findings of iridescent crystals resemble those of myeloma and are very infrequent (approximately 1%–2% of affected patients).</p>
			<p class="body-text"><span class="italic">Cryoglobulins,</span> proteins that precipitate upon exposure to cold, occur nonspecifically in autoimmune disorders, immunoproliferative disorders, and hepatitis&#160;B infection. Ophthalmic findings include signs of retinal hyperviscosity, occasional crystalline corneal deposits, amorphous limbal masses, and signs of autoimmune disease.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> There are many causes of corneal crystalline deposits. The appearance and location of the deposits can help distinguish the underlying etiology.</p>
			<p class="body-text">Serum protein electrophoresis, complete blood count (CBC), and general screening for albumin/globulin and calcium levels are performed when clinical suspicion of immunoglobulin excess arises. Further testing for systemic evaluation depends on clinical suspicion and the initial findings.</p>
			<p class="h5-text"><span class="h5-head">management</span> No ophthalmic treatment is necessary unless the amorphous deposits interfere with vision and need to be removed with LK. Crystals resolve slowly after successful treatment of an underlying malignancy. See Table&#160;8-2 for a list of other causes of corneal crystals.</p>
			<p class="reference-single--no-space-">Choulakian MY. Hematologic diseases and malignancies. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:688–695.</p>
			</div>
			<p class="h1 ParaOverride-12">Endocrine Diseases</p>
			 <div id="Chapt8_Top7">
			<p class="h2-h1">Diabetes Mellitus</p>
			<p class="body-text--no-indent-">The most common disorder of carbohydrate metabolism, diabetes mellitus (DM), has nonspecific corneal manifestations. See BCSC Section&#160;1, <span class="italic">Update on General Medicine,</span> for detailed discussion of DM.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Diabetic keratopathy includes superficial punctate epitheliopathy, epithelial erosions, hypoesthesia, persistent epithelial defects, and corneal edema. These changes occur with increasing severity and duration of the disease. Surgical removal of diabetic epithelium results in the loss of the basal cells and basement membrane, often leading to prolonged healing difficulties. Faint vertical folds in the Descemet membrane and deep stroma (Waite-&#173;Beetham lines) are not specific to DM but may represent early corneal endothelial dysfunction and increased stromal hydration.</p>
			<p class="h5-text"><span class="h5-head">laboratory evaluation</span> An increase in glycosylated hemoglobin is related to poor control of DM and may correlate with poor corneal healing in addition to progressive retinopathy.</p>
			<p class="h5-text"><span class="h5-head">management</span> Diabetes mellitus is not a contraindication to PK or other corneal surgery. Measures that can improve diabetic epitheliopathy include the following:</p>
			<ul>
				<li class="bullet-list-first">perioperative management of meibomian gland dysfunction (increased comorbidity with DM)</li>
				<li class="bullet-list-mid">minimizing epithelial debridement at surgery</li>
				<li class="bullet-list-mid">increasing lubrication</li>
				<li class="bullet-list-mid">avoiding toxic medications</li>
				<li class="bullet-list-last ParaOverride-11">using therapeutic contact lenses, exercising caution because of the risk of infection<p class="reference-single--no-space- _idGenParaOverride-1">Srinivasan S, Shehadeh-Mashor R, Slomovic AR. Corneal manifestations of metabolic diseases. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:620–644.</p></li>
			</ul>
			<p class="h2">Multiple Endocrine Neoplasia</p>
			<p class="body-text--no-indent-">Multiple endocrine neoplasia (MEN) is a group of disorders that affect the body’s endocrine system. MEN typically involves tumors (neoplasia) in at least 2&#160;endocrine glands. These growths can be benign or malignant. The condition is classified as MEN&#160;1, MEN&#160;2A, or MEN&#160;2B, depending on the glands involved.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> MEN&#160;2 results from a spontaneous mutation of the <span class="italic">RET</span> gene, or it is inherited in an autosomal dominant fashion.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> MEN&#160;2B is characterized by medullary carcinoma of the thyroid gland, pheochromocytoma, and mucosal neuromas. Patients with MEN&#160;2B have enlarged corneal nerves. In addition, they often have a marfanoid habitus. Conjunctival and eyelid neuromas and keratoconjunctivitis sicca may occur. Patients with MEN&#160;2A also have been noted to have enlarged corneal nerves. <span class="xref-table">Table&#160;8-7</span> lists other causes of prominent corneal nerves (<span class="xref-figure">Fig&#160;8-16</span>) from either true enlargement or increased visibility.</p>
			<p class="h2">Parathyroid Disease</p>
			<p class="body-text--no-indent-">Parathyroid hormone and calcitonin (one of the hormones produced by the thyroid gland) play key roles in regulating the amount of calcium in the blood and within the bones.</p>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> Primary hyperparathyroidism is most commonly associated with benign proliferation of chief cells within a single parathyroid gland and, in rare cases, with MEN. Secondary hyperparathyroidism can be caused by renal disease in which excessive amounts of calcium are lost and the glands release a compensatory amount of parathyroid hormone. Parathyroid hyperplasia can occur in the presence of hypercalcemia and hypophosphatemia associated with milk-&#173;alkali syndrome, sarcoidosis, and excessive intake of vitamin&#160;D. Calcium deposition can occur despite normal parathyroid function and normal levels of systemic serum calcium. See Chapter&#160;6 for further discussion.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Calcium deposits within the interpalpebral area of the cornea are known as <span class="italic">band keratopathy.</span> The calcium is deposited in the superficial layers of the cornea and the Bowman layer.</p>
			<p class="h5-text"><span class="h5-head">management</span> If symptomatic with decreased vision or discomfort, the calcium can be removed with EDTA.</p>
			<p class="reference-single--no-space-">Darvish-Zargar M, Bartow RM. Endocrine disease and the cornea. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:696–704.</p>
			</div>
			<p class="h1 ParaOverride-13">Dermatologic Diseases</p>
			 <div id="Chapt8_Top8">
			<p class="body-text--no-indent-">Dermatologic disorders commonly have associated ophthalmic findings, particularly involving the eyelids.</p>
			<p class="h2">Ichthyosis</p>
			<p class="body-text--no-indent-">Ichthyosis represents a diverse group of hereditary skin disorders characterized by excessively dry skin and accumulation of scales. These diseases are usually diagnosed during the first year of life.</p>
			<p class="body-text"><span class="italic">Ichthyosis vulgaris,</span> an autosomal dominant trait, is the most common hereditary scaling disorder, affecting 1 in 250–300&#160;people. Ocular involvement varies with this form of ichthyosis.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Eyelid scaling, cicatricial ectropion, and conjunctival thickening are common in ichthyosis. Primary corneal opacities are noted in 50% of patients with X-linked ichthyosis but are rarely seen in patients with ichthyosis vulgaris. Dotlike or filament-&#173;shaped opacities appear diffusely in pre–Descemet membrane or in deep stroma and become more apparent with age without affecting vision. Nodular corneal degeneration and band keratopathy have been described. Secondary corneal changes such as vascularization and scarring from severe ectropion-&#173;related exposure can develop.</p>
			<p class="h5-text"><span class="h5-head">management</span> The goal of treatment in all ichthyosis disorders is to hydrate the skin and eyelids, remove scales, and slow the turnover of epidermis, when appropriate. These disorders are not responsive to corticosteroids.</p>
			<p class="h2 ParaOverride-7">Ectodermal Dysplasia</p>
			<p class="body-text--no-indent-">Ectodermal dysplasia is a heterogeneous group of conditions characterized by the following:</p>
			<ul>
				<li class="bullet-list-first">presence of abnormalities at birth</li>
				<li class="bullet-list-mid">nonprogressive course</li>
				<li class="bullet-list-mid">diffuse involvement of the epidermis plus at least 1 of its appendages (hair, nails, teeth, sweat glands)</li>
				<li class="bullet-list-last ParaOverride-11">various inheritance patterns</li>
			</ul>
			<p class="h5-text"><span class="h5-head">pathogenesis</span> Ectodermal dysplasia is a rare hereditary condition that displays variable defects in the morphogenesis of ectodermal structures, including hair, skin, nails, and teeth. It is a component of at least 150&#160;distinct hereditary syndromes.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> Many ocular abnormalities have been described in the ectodermal dysplasias, including sparse eyelashes and eyebrows, blepharitis, ankyloblepharon, hypoplastic lacrimal ducts, diminished tear production, abnormal meibomian glands, dry conjunctivae, pterygia, corneal scarring and neovascularization, cataract, and glaucoma. The ocular surface changes may be due to limbal stem cell deficiency. Although the dermatologic manifestations are nonprogressive, the corneal conditions can worsen with time.</p>
			<p class="h5-text"><span class="h5-head">management</span> The ocular surface changes and blepharitis can be managed with tear replacement and preservation, together with eyelid hygiene. Keratolimbal autograft transplantation in combination with PK can be performed.</p>
			<p class="h2 ParaOverride-7">Xeroderma Pigmentosum</p>
			<p class="h5-text ParaOverride-1"><span class="h5-head">pathogenesis</span> Xeroderma pigmentosum is a rare, autosomal recessive disease characterized by extreme skin photosensitivity resulting from an impaired ability to repair sunlight-&#173;induced damage to DNA.</p>
			<p class="h5-text"><span class="h5-head">clinical presentation</span> During the first or second decade of life, the patient’s sun-&#173;exposed skin develops areas of focal hyperpigmentation, atrophy, actinic keratosis, and telangiectasia—as though the patient received a heavy dose of radiation. Later, many cutaneous neoplasms appear; these include squamous cell carcinoma, basal cell carcinoma, and melanoma. Ophthalmic manifestations include photophobia, tearing, blepharospasm, and signs and symptoms of keratoconjunctivitis sicca. The conjunctiva is dry and inflamed with telangiectasia and hyperpigmentation. Pingueculae and pterygia often occur. Corneal complications include exposure keratitis, ulceration, neovascularization, scarring, and even perforation. Keratoconus and gelatinous droplike corneal dystrophy have also been reported. Ocular neoplasms occur in 11% of affected patients, most frequently at the limbus. Squamous cell carcinoma is the most frequent histologic type, followed by basal cell carcinoma and melanoma. The eyelids can be involved, with progressive atrophy, madarosis, trichiasis, scarring, symblepharon, entropion, ectropion, and sometimes even loss of the entire lower eyelid.</p>
			<p class="body-text">Other dermatologic disorders that have ocular manifestations include seborrhea, staphylococcal hypersensitivity, rosacea, and atopic disease. The cornea may show marginal ulceration, neovascularization, and pannus formation. These topics are discussed in depth in Chapter&#160;3.</p>
			<p class="h5-text"><span class="h5-head">management</span> Skin protection from ultraviolet radiation, including use of sunscreen and protective clothing, is the mainstay of therapy. In addition, patients with xeroderma pigmentosum should be monitored for skin and eyelid malignancies.</p>
			<p class="reference-first">Mannis MJ, Macsai MS, Huntley AC, eds. <span class="italic">Eye and Skin Disease.</span> Philadelphia: Lippincott-&#173;Raven; 1996.</p>
			<p class="reference-last--no-space-">Sadowsky AE. Dermatologic disorders and the cornea. In: Mannis MJ, Holland EJ, eds. <span class="italic">Cornea.</span> Vol&#160;1. 4th&#160;ed. Philadelphia: Elsevier; 2017:705–718.</p>
		</div>
		</div>
		<div id="_idContainer001" class="Basic-Text-Frame">
			<table id="table001" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-3" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-4" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-5" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-6" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-7" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="11">
							<p class="table-title"><span class="table-number">Table 8-1</span> Summary of Mucopolysaccharidosis Syndromes</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">MPS Syndrome</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Inheritance</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Enzyme Defect</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Accumulated Material</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Corneal Changes</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Other Ophthalmic Changes</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">MPS IH (Hurler syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body"><span class="greek--tb-">α</span>-<span class="small-cap">l</span>-Iduronidase</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Dermatan and heparan sulfate</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Severe clouding within first few years of life; diffuse punctate stromal opacities; epithelium and endothelium not affected</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Pigmentary retinopathy, glaucoma, optic nerve swelling and atrophy, hypertelorism</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">MPS IS (Scheie syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body"><span class="greek--tb-">α</span>-<span class="small-cap">l</span>-Iduronidase</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Dermatan and heparan sulfate</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Slowly progressive corneal opacification causing decreased vision by second decade of life; corneal edema; corneal changes may be more prominent in periphery</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Glaucoma may occur</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">MPS IH/S (Hurler-Scheie syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body"><span class="greek--tb-">α</span>-<span class="small-cap">l</span>-Iduronidase</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Dermatan and heparan sulfate</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Diffuse corneal opacification</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Retinopathy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-13">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">MPS II (Hunter syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">X-linked recessive</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Iduronate-2-sulfatase</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Dermatan and heparan sulfate</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Does not present as a congenital corneal opacity; corneal opacity may occur later in life in milder phenotypes</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Exophthalmos, hypertelorism, optic nerve swelling and atrophy, retinopathy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-13">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">MPS III A–D (Sanfilippo syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Multiple enzyme defects</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Heparan sulfate</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Uncommon</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Moderate to severe pigmentary retinopathy with abnormal ERG response</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-13">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">MPS IV A–B (Morquio syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Galactose-6-sulfatase (MPS IV A)</p>
							<p class="table-body"><span class="greek--tb-">β</span>-Galactosidase (MPS IV B)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Keratan sulfate (MPS IV A and IV B)</p>
							<p class="table-body">Chondroitin sulfate (MPS IV A)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Opacities after age 10&#160;years in 10% of patients; usually mild</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Retinopathy, shallow orbits</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">MPS VI (Maroteaux-Lamy syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body"><span class="CharOverride-3">N</span>-Acetylgalactosamine-4-sulfatase</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Dermatan sulfate</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Severe corneal clouding within first years of life; corneal edema</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Narrow-angle glaucoma, optic neuropathy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">MPS VII (Sly syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body"><span class="greek--tb-">β</span>-Glucuronidase</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Dermatan sulfate, keratan sulfate, chondroitin sulfate</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Corneal clouding</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-14">—</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">MPS IX (Natowicz syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Hyaluronidase 1</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Chondroitin sulfate</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">None reported</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-14">—</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-7" colspan="11">
							<p class="table-footnote">ERG = electroretinogram; MPS = mucopolysaccharidosis.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer004">
				<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9336.png" alt="" />
				</div>
				<div id="_idContainer003" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-1</span> Slit-lamp photograph from a patient with Hurler syndrome, showing diffuse, patchy corneal clouding. <span class="figure-source-note">(Courtesy of Stephen&#160;E. Orlin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer007">
				<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9337.png" alt="" />
				</div>
				<div id="_idContainer006" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-2</span> Slit-lamp photograph from a patient with Fabry disease, showing cornea verticillata in the basal layers of the epithelium. <span class="figure-source-note">(Courtesy of Stephen&#160;E. Orlin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer010">
				<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9338.png" alt="" />
				</div>
				<div id="_idContainer009" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-3</span> Clinical photograph from a patient with familial lecithin-&#173;cholesterol acyltransfer-<br />ase (LCAT) deficiency, showing peripheral arcus and nebular stromal haze. <span class="figure-source-note">(Courtesy of Gerald Zaid&#173;man, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer013">
				<div id="_idContainer011" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9339.png" alt="" />
				</div>
				<div id="_idContainer012" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-4</span> Nonnephropathic cystinosis. Slit-lamp photograph showing diffuse stromal refractile crystals. <span class="figure-source-note">(Courtesy of Stephen&#160;E. Orlin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer014" class="Basic-Text-Frame">
			<table id="table002" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-17" />
					<col class="_idGenTableRowColumn-18" />
					<col class="_idGenTableRowColumn-19" />
					<col class="_idGenTableRowColumn-20" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="4">
							<p class="table-title"><span class="table-number">Table 8-2</span> Differential Diagnosis of Corneal Crystals</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Medical Disorders</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Specific Conditions and Medications</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Lipid keratopathies</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Familial lipoprotein disorders</p>
							<p class="table-body">LCAT deficiency</p>
							<p class="table-body">Schnyder corneal dystrophy</p>
							<p class="table-body">Tangier disease</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table CellOverride-8">
							<p class="table-body">Disorders of protein metabolism</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body">Cystinosis</p>
							<p class="table-body">Gout</p>
							<p class="table-body">Hyperuricemia</p>
							<p class="table-body">Tyrosinemia</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-21">
						<td class="Basic-Table CellOverride-9">
							<p class="table-body">Immunoglobulin disorders</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-body">Benign monoclonal gammopathy</p>
							<p class="table-body">Cryoglobulinemia</p>
							<p class="table-body">Multiple myeloma</p>
							<p class="table-body">Rheumatoid arthritis</p>
							<p class="table-body">Waldenström macroglobulinemia</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-22">
						<td class="Basic-Table CellOverride-9">
							<p class="table-body">Infectious crystalline keratopathy</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-body">Bacterial infection <span class="CharOverride-3">(Streptococcus viridans)</span></p>
							<p class="table-body">Fungal infection</p>
							<p class="table-body">Viral infection</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-22">
						<td class="Basic-Table CellOverride-9">
							<p class="table-body">Medication toxicity</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-body">Chloroquine</p>
							<p class="table-body">Chlorpromazine</p>
							<p class="table-body">Topical ciprofloxacin</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-10">
							<p class="table-body">Miscellaneous causes </p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-body">Bietti corneal dystrophy</p>
							<p class="table-body">Calcium deposits</p>
							<p class="table-body"><span class="CharOverride-3">Dieffenbachia</span> plant sap</p>
							<p class="table-body">Oxalosis</p>
							<p class="table-body">Porphyria</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-7" colspan="4">
							<p class="table-footnote">LCAT = lecithin–cholesterol acyltransferase.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer015" class="Basic-Text-Frame">
			<table id="table003" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-23" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-24" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-25" />
					<col class="_idGenTableRowColumn-26" />
					<col class="_idGenTableRowColumn-27" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="7">
							<p class="table-title"><span class="table-number">Table 8-3</span> Disorders of Amino Acid Metabolism</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-11">
							<p class="table-column-head">Type</p>
						</td>
						<td class="Basic-Table CellOverride-11" />
						<td class="Basic-Table CellOverride-11">
							<p class="table-column-head">Heredity</p>
						</td>
						<td class="Basic-Table CellOverride-11" />
						<td class="Basic-Table CellOverride-11">
							<p class="table-column-head">Ocular Findings</p>
						</td>
						<td class="Basic-Table CellOverride-11" />
						<td class="Basic-Table CellOverride-11">
							<p class="table-column-head">Associated Nonocular Conditions</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-21">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Cystinosis</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Rare autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Polychromatic cystine crystals in conjunctiva, trabecular meshwork, corneal stroma, and iris</p>
							<p class="table-body">Photophobia (usually)</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Dwarfism</p>
							<p class="table-body">Renal dysfunction</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-28">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Tyrosinemia</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Photophobia, tearing, conjunctival injection, tarsal papillary hypertrophy, pseudodendrites</p>
							<p class="table-body">Epithelial breakdown with secondary corneal neovascularization and scarring</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Hyperkeratotic lesions of palms, soles, and elbows</p>
							<p class="table-body">Cognitive impairment</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-29">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Alkaptonuria</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Rare autosomal recessive</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Ochronotic (brownish) deposits of alkapton in corneal epithelium or in Bowman layer near limbus</p>
							<p class="table-body">Rectus muscle tendons and adjacent sclera develop smudgelike pigmentation</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Arthropathy</p>
							<p class="table-body">Renal calculi</p>
							<p class="table-body">Pigmentation of cartilaginous structures, including earlobes, trachea, nose, and tendons</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer018">
				<div id="_idContainer016" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9340.png" alt="" />
				</div>
				<div id="_idContainer017" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-5</span> Slit-lamp photograph showing a pseudodendrite in a patient with tyrosinemia. <span class="figure-source-note">(Cou</span><span class="figure-source-note">r</span><span class="figure-source-note">-<br />tesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer021">
				<div id="_idContainer019" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9341.png" alt="" />
				</div>
				<div id="_idContainer020" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-6</span> Slit-lamp photograph from a female patient with alkaptonuria, showing ochronosis (scleral pigmentation) at the insertion of the lateral rectus muscle. <span class="figure-source-note">(Courtesy of Irving&#160;M. Raber, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer022" class="Basic-Text-Frame">
			<table id="table004" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-30" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-31" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-32" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-33" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="7">
							<p class="table-title"><span class="table-number">Table 8-4</span> Amyloid in the Eye</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Type</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Heredity</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Ocular Distribution/Findings</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Other Associated Ocular and Systemic Conditions</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-34">
						<td class="Basic-Table CellOverride-3 _idGenCellOverride-2" rowspan="5">
							<p class="table-body">Primary localized amyloidosis</p>
						</td>
						<td class="Basic-Table CellOverride-3 _idGenCellOverride-2" rowspan="5" />
						<td class="Basic-Table CellOverride-3 _idGenCellOverride-2" rowspan="2">
							<p class="table-body">Nonfamilial</p>
						</td>
						<td class="Basic-Table CellOverride-3 _idGenCellOverride-2" rowspan="5" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Conjunctival plaque</p>
						</td>
						<td class="Basic-Table CellOverride-3 _idGenCellOverride-2" rowspan="5" />
						<td class="Basic-Table CellOverride-3 _idGenCellOverride-2" rowspan="5">
							<p class="table-body">None</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Polymorphic amyloid degeneration</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5" rowspan="3">
							<p class="table-body">Familial</p>
						</td>
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Lattice corneal dystrophy and lattice variants</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Granular corneal dystrophy type 2 (Avellino)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Gelatinous droplike dystrophy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5" rowspan="3">
							<p class="table-body">Primary systemic amyloidosis</p>
						</td>
						<td class="Basic-Table CellOverride-5" rowspan="3" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Nonfamilial</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Eyelid skin and conjunctiva (very rare)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Occult plasma cell dyscrasias</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-13">
						<td class="Basic-Table CellOverride-5" rowspan="2">
							<p class="table-body">Familial</p>
						</td>
						<td class="Basic-Table CellOverride-5" rowspan="2" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Ophthalmoplegia (orbital and muscle infiltrates), ptosis, vitreous veils, dry eye, pupillary abnormalities</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Cardiomyopathy, peripheral neuropathy, gastrointestinal disease</p>
							<p class="table-body">Skin involvement</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Meretoja syndrome, cranial neuropathies</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Meretoja syndrome (facial palsies, skin nodules, rarely renal involvement)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" rowspan="2">
							<p class="table-body">Secondary localized amyloidosis</p>
						</td>
						<td class="Basic-Table CellOverride-5" rowspan="2" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Nonfamilial</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Conjunctiva, eyelid skin, cornea</p>
						</td>
						<td class="Basic-Table CellOverride-5" rowspan="2" />
						<td class="Basic-Table CellOverride-5" rowspan="2">
							<p class="table-body">Trachoma, psoriasis, trauma, phlyctenulosis, retinopathy of prematurity, keratoconus, bullous keratopathy, interstitial keratitis, Hansen disease (leprosy), trichiasis, tertiary syphilis, uveitis, climatic droplet keratopathy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Familial</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">None</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-5 _idGenCellOverride-3" rowspan="5">
							<p class="table-body">Secondary systemic amyloidosis</p>
						</td>
						<td class="Basic-Table CellOverride-5" rowspan="4" />
						<td class="Basic-Table CellOverride-5" rowspan="4">
							<p class="table-body">Nonfamilial</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Vitreous body (rare)</p>
							<p class="table-body">(Corneal deposits are not amyloid)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Multiple myeloma</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" rowspan="3" />
						<td class="Basic-Table CellOverride-5" rowspan="3">
							<p class="table-body">Conjunctiva, eyelid skin (rare)</p>
						</td>
						<td class="Basic-Table CellOverride-5" rowspan="3" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Infectious diseases (tuberculosis, Hansen disease [leprosy], syphilis)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Inflammatory diseases (rheumatoid arthritis, other connective tissue disorders)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Hodgkin disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Familial</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">(Corneal nerve enlargement is not due to amyloid)</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Multiple endocrine neoplasia type 2A</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer025">
				<div id="_idContainer023" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9342.png" alt="" />
				</div>
				<div id="_idContainer024" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-7</span> Clinical photograph of the inferior palpebral conjunctiva, showing moderate thickening with yellowish amyloid deposition. <span class="figure-source-note">(Courtesy of Stephen E. Orlin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer028">
				<div id="_idContainer026" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-6849.png" alt="" />
				</div>
				<div id="_idContainer027" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-8</span> <span class="figure-caption-bold">A,</span>&#160;Diffuse lattice lines in Meretoja syndrome. <span class="figure-caption-bold">B,</span>&#160;Typical facies. <span class="figure-source-note">(Reproduced with permission from Weiss JS, Møller H, Lisch W, et al. The ICD3 classification of the corneal dystrophies. </span><span class="figure-source-emphasis">Cornea. </span><span class="figure-source-note">2008;<br />27(10&#160;Suppl&#160;2):S16.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer031">
				<div id="_idContainer029" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-3563.png" alt="" />
				</div>
				<div id="_idContainer030" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-9</span> Wilson hepatolenticular degeneration. Deposits of copper in the Descemet membrane (Kayser-&#173;Fleischer ring). <span class="figure-source-note">(Reproduced with permission from Krachmer JH, Mannis MJ, Holland EJ, eds. </span><span class="figure-source-emphasis">Cornea.</span><span class="figure-source-note"> 3rd&#160;ed. Vol&#160;1. Philadelphia: Elsevier/Mosby; 2011:299.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer034">
				<div id="_idContainer032" class="Basic-Text-Frame">
					<table id="table005" class="Basic-Table TableOverride-1">
						<colgroup>
							<col class="_idGenTableRowColumn-36" />
							<col class="_idGenTableRowColumn-2" />
							<col class="_idGenTableRowColumn-37" />
							<col class="_idGenTableRowColumn-2" />
							<col class="_idGenTableRowColumn-38" />
						</colgroup>
						<thead>
							<tr class="Basic-Table _idGenTableRowColumn-8">
								<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="5">
									<p class="table-title"><span class="table-number">Table 8-5</span> Skeletal and Connective Tissue Disorders of Interest to the Ophthalmologist</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-9">
								<td class="Basic-Table CellOverride-2">
									<p class="table-column-head">Name (OMIM #)</p>
								</td>
								<td class="Basic-Table CellOverride-2" />
								<td class="Basic-Table CellOverride-2">
									<p class="table-column-head">Corneal Findings</p>
								</td>
								<td class="Basic-Table CellOverride-2" />
								<td class="Basic-Table CellOverride-2">
									<p class="table-column-head">Other Ocular Findings</p>
								</td>
							</tr>
						</thead>
						<tbody>
							<tr class="Basic-Table _idGenTableRowColumn-34">
								<td class="Basic-Table CellOverride-3">
									<p class="table-body">Albright hereditary osteodystrophy (300800)</p>
								</td>
								<td class="Basic-Table CellOverride-3" />
								<td class="Basic-Table CellOverride-3">
									<p class="table-body">None</p>
								</td>
								<td class="Basic-Table CellOverride-3" />
								<td class="Basic-Table CellOverride-3">
									<p class="table-body">Zonular cataracts with multicolored flecks in 25% of affected patients</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-13">
								<td class="Basic-Table CellOverride-4">
									<p class="table-body">Apert syndrome (101200)</p>
								</td>
								<td class="Basic-Table CellOverride-4" />
								<td class="Basic-Table CellOverride-4">
									<p class="table-body">Exposure keratitis with severe proptosis</p>
									<p class="table-body">Keratoconus (very rare)</p>
									<p class="table-body">Megalocornea (very rare)</p>
								</td>
								<td class="Basic-Table CellOverride-4" />
								<td class="Basic-Table CellOverride-4">
									<p class="table-body">Strabismus (exotropia with V pattern)</p>
									<p class="table-body">Absence of extraocular muscles; proptosis, ocular hypopigmentation, optic atrophy</p>
									<p class="table-body">Rare: nystagmus, ptosis, cataract, ectopia lentis, coloboma of iris</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-13">
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Carpenter syndrome; acrocephalopolysyndactyly type&#160;II (201000)</p>
								</td>
								<td class="Basic-Table CellOverride-5" />
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Exposure keratitis secondary to severe proptosis</p>
									<p class="table-body">Microcornea (rare)</p>
									<p class="table-body">Corneal leukoma (rare)</p>
								</td>
								<td class="Basic-Table CellOverride-5" />
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Epicanthal folds, downward slant, hypertelorism or hypotelorism, optic atrophy, strabismus</p>
									<p class="table-body">Rare: coloboma of the iris and choroid, congenital cataract, lens subluxation, nystagmus, retinal detachment</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-14">
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Cockayne syndrome</p>
									<p class="table-indent-1">Type A (216400)</p>
									<p class="table-indent-1">Type B (133540)</p>
								</td>
								<td class="Basic-Table CellOverride-5" />
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Raised inferior corneal lesion, band keratopathy, recurrent erosions</p>
								</td>
								<td class="Basic-Table CellOverride-5" />
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Cataracts, retinal dystrophy, nystagmus, iris atrophy, hyperopia, enophthalmos, strabismus</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-13">
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Crouzon syndrome (123500)</p>
								</td>
								<td class="Basic-Table CellOverride-5" />
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Exposure keratitis with severe proptosis</p>
									<p class="table-body">Keratoconus (very rare)</p>
									<p class="table-body">Microcornea (very rare)</p>
								</td>
								<td class="Basic-Table CellOverride-5" />
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Strabismus (exotropia with V pattern)</p>
									<p class="table-body">Exophthalmos, hypertelorism, optic atrophy in 30% of affected patients</p>
									<p class="table-body">Rare: nystagmus, glaucoma, cataract, ectopia lentis, aniridia, anisocoria, myelinated nerve fibers</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-39">
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Ehlers-Danlos syndrome (EDS)</p>
									<p class="table-indent-1">EDS I (130000)</p>
									<p class="table-indent-1">EDS II (130010)</p>
									<p class="table-indent-1">EDS III (130020)</p>
									<p class="table-indent-1">EDS IV (130050)</p>
									<p class="table-indent-1">EDS V (305200)</p>
									<p class="table-indent-1">EDS VI (225400)</p>
									<p class="table-indent-1">EDS VII–AD (130060)</p>
									<p class="table-indent-1">EDS VII–AR (225410)</p>
									<p class="table-indent-1">EDS VIII (130080)</p>
								</td>
								<td class="Basic-Table CellOverride-5" />
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Brittle cornea in type VI</p>
									<p class="table-body">Keratoconus in types I and VI</p>
									<p class="table-body">Keratoglobus in type VI</p>
								</td>
								<td class="Basic-Table CellOverride-5" />
								<td class="Basic-Table CellOverride-5">
									<p class="table-body">Epicanthal folds, blue sclera, retinal detachment, glaucoma, ectopia lentis, angioid streaks (rare)</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-40">
								<td class="Basic-Table CellOverride-12">
									<p class="table-body">Goldenhar-Gorlin syndrome; oculoauriculovertebral sequence; hemifacial microsomia (164210)</p>
								</td>
								<td class="Basic-Table CellOverride-12" />
								<td class="Basic-Table CellOverride-12">
									<p class="table-body">Limbal dermoid</p>
								</td>
								<td class="Basic-Table CellOverride-12" />
								<td class="Basic-Table CellOverride-12">
									<p class="table-body">Upper &gt; lower eyelid coloboma, strabismus (25% of affected patients), Duane retraction syndrome, microphthalmos, anophthalmos, lacrimal system dysfunction, optic nerve hypoplasia, tortuous retinal vessels, macular hypoplasia and heterotropia, choroidal hyperpigmentation, iris and retinal colobomas</p>
								</td>
							</tr>
							<tr class="Basic-Table _idGenTableRowColumn-41">
								<td class="Basic-Table CellOverride-13">
									<p class="table-body">Hallermann-Streiff-François syndrome; oculomandibulodyscephaly (234100)</p>
								</td>
								<td class="Basic-Table CellOverride-13" />
								<td class="Basic-Table CellOverride-13">
									<p class="table-body">One case of sclerocornea</p>
								</td>
								<td class="Basic-Table CellOverride-13" />
								<td class="Basic-Table CellOverride-13">
									<p class="table-body">Congenital cataracts, spontaneous resorption of lens cortex with secondary membranous cataract formation, glaucoma, uveitis, retinal folds, optic nerve dysplasia, microphthalmos</p>
								</td>
							</tr>
						</tbody>
					</table>
				</div>
				<div id="_idContainer033" class="Basic-Text-Frame">
					<p class="table-cont-line">(Continued)</p>
				</div>
			</div>
		</div>
		<div id="_idContainer035" class="Basic-Text-Frame">
			<table id="table006" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-36" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-37" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-38" />
				</colgroup>
				<thead>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="5">
							<p class="table-title"><span class="table-number">Table 8-5</span> <span class="CharOverride-3">(continued)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Name (OMIM #)</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Corneal Findings</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Other Ocular Findings</p>
						</td>
					</tr>
				</thead>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table CellOverride-9 _idGenCellOverride-4">
							<p class="table-body">Hypophosphatasia</p>
							<p class="table-indent-1">Infantile (241500)</p>
							<p class="table-indent-1">Childhood (241510)</p>
							<p class="table-indent-1">Adult (146300)</p>
						</td>
						<td class="Basic-Table CellOverride-9 _idGenCellOverride-4" />
						<td class="Basic-Table CellOverride-9 _idGenCellOverride-4">
							<p class="table-body">Band keratopathy with conjunctival calcifications in infantile form</p>
						</td>
						<td class="Basic-Table CellOverride-9 _idGenCellOverride-4" />
						<td class="Basic-Table CellOverride-9 _idGenCellOverride-4">
							<p class="table-body">Blue sclera, cataracts, optic atrophy secondary to craniostenosis, atypical retinitis pigmentosa; ocular complications present only in infantile and childhood forms, not in adult form</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Marfan syndrome (154700)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Megalocornea (uncommon)</p>
							<p class="table-body">Flat cornea</p>
							<p class="table-body">Keratoconus (uncommon)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Ectopia lentis, strabismus, cataracts, myopia, retinal detachment, glaucoma, blue sclera</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Nail–patella syndrome; onycho-osteodysplasia (161200)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Microcornea</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Cataracts, microphthalmos</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Oculodento-osseous dysplasia</p>
							<p class="table-indent-1">AD (164200)</p>
							<p class="table-indent-1">AR (257850)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Microcornea</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Hypotelorism, convergent strabismus, anterior segment dysgenesis, glaucoma, cataracts, remnants of the hyaloid system</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-40">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Osteogenesis imperfecta</p>
							<p class="table-indent-1">Type&#160;I (259400)</p>
							<p class="table-indent-1">Type&#160;II (166200)</p>
							<p class="table-indent-1">Type&#160;III (259420)</p>
							<p class="table-indent-1">Type&#160;IV (166220)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Decreased central corneal thickness</p>
							<p class="table-body">Keratoconus (rare)</p>
							<p class="table-body">Megalocornea (rare)</p>
							<p class="table-body">Posterior embryotoxon (rare)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Blue sclera</p>
							<p class="table-body">Rare: congenital glaucoma, cataract, choroidal sclerosis, subhyaloid hemorrhage, hyperopia, ectopia lentis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Parry-Romberg syndrome; progressive facial hemiatrophy (141300)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Neuroparalytic keratitis</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Enophthalmos, oculomotor palsies, pupillary abnormalities, Horner syndrome, heterochromia, intraocular inflammation, optic nerve hypoplasia, choroidal atrophy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Pierre Robin malformation (261800)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Megalocornea (rare)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Congenital glaucoma, high myopia, vitreoretinal degeneration, retinal detachment, esotropia, congenital cataracts, microphthalmos</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Rothmund-Thomson syndrome (268400)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Degenerative lesions of cornea</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Cataracts</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Treacher Collins syndrome; mandibulofacial dysostosis (154500)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Microcornea</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Lower eyelid coloboma, bony orbit dysplasia, absent lower eyelid cilia, absent lower eyelid lacrimal puncta, iris coloboma, microphthalmos, strabismus, downward slant</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-42">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Werner syndrome (277700)</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Corneal edema secondary to endothelial decompensation following cataract surgery</p>
							<p class="table-body">Poor wound healing</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Presenile posterior subcapsular cataracts (age 20–30&#160;years), proptosis, blue sclera</p>
							<p class="table-body">Rare: nystagmus, astigmatism, telangiectasia of iris, macular degeneration, pigmentary retinopathy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-7" colspan="5">
							<p class="table-footnote">AD = autosomal dominant; AR = autosomal recessive; OMIM = Online Mendelian Inheritance in Man.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer038">
				<div id="_idContainer036" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9343.png" alt="" />
				</div>
				<div id="_idContainer037" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-10</span> Slit-lamp photograph from a patient with Marfan syndrome, showing superior displacement of the lens. Note the stretched zonular fibers <span class="figure-caption-italic">(arrow).</span> <span class="figure-source-note">(Courtesy of Stephen&#160;E. Orlin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer041">
				<div id="_idContainer039" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-11</span> Clinical photograph showing blue sclera in a patient with osteogenesis imperfecta. <span class="figure-source-note">(Courtesy of Stephen&#160;E. Orlin, MD.)</span></p>
				</div>
				<div id="_idContainer040" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9344.jpg" alt="" />
				</div>
			</div>
		</div>
		<div id="_idContainer042" class="Basic-Text-Frame">
			<table id="table007" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-43" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-43" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 8-6</span> Conditions and Medications Associated With Blue Sclera</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-34">
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-head">Local</p>
						</td>
						<td class="Basic-Table CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">High myopia</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Inactive scleritis</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Oculodermal melanocytosis (nevus of Ota)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Previous eye surgeries</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Thin sclerae in neonates</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-45">
						<td class="Basic-Table CellOverride-14" />
						<td class="Basic-Table CellOverride-14">
							<p class="table-head">Systemic</p>
						</td>
						<td class="Basic-Table CellOverride-14" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Alkaptonuria</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Brittle cornea syndrome</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Ehlers-Danlos syndrome type VI</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Hypophosphatasia</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Marfan syndrome</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Osteogenesis imperfecta</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Primary adrenal insufficiency (Addison disease)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-45">
						<td class="Basic-Table CellOverride-14" />
						<td class="Basic-Table CellOverride-14">
							<p class="table-head">Medications</p>
						</td>
						<td class="Basic-Table CellOverride-14" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Amiodarone</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Antimalarials</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Minocycline</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Phenothiazines</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer045">
				<div id="_idContainer043" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9345.png" alt="" />
				</div>
				<div id="_idContainer044" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-12</span> <span class="figure-caption-bold">A,</span>&#160;Clinical photograph showing an inferotemporal limbal dermoid in a patient with Goldenhar-&#173;Gorlin syndrome. Note the multiple hair follicles. <span class="figure-caption-bold">B,</span>&#160;External photograph showing preauricular skin tags in a patient with Goldenhar-&#173;Gorlin syndrome. <span class="figure-source-note">(Courtesy of Stephen&#160;E. Orlin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer048">
				<div id="_idContainer046" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9348.png" alt="" />
				</div>
				<div id="_idContainer047" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-13</span> Clinical photograph showing a foamy Bitôt spot in the bulbar conjunctiva, close to the limbus, in a patient with anorexia. <span class="figure-source-note">(Courtesy of Stephen&#160;E. Orlin, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer051">
				<div id="_idContainer049" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-14</span> Slit-lamp photograph from a patient with multiple myeloma, showing polychromatic stromal crystals. <span class="figure-source-note">(Courtesy of Stephen&#160;E. Orlin, MD.)</span></p>
				</div>
				<div id="_idContainer050" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9349.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer054">
				<div id="_idContainer052" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9350.jpg" alt="" />
				</div>
				<div id="_idContainer053" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 8-15</span> Clinical photograph from a patient with Waldenström macroglobulinemia, showing amorphous deposits in the stroma. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer055" class="Basic-Text-Frame">
			<table id="table008" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-46" />
					<col class="_idGenTableRowColumn-31" />
					<col class="_idGenTableRowColumn-47" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table CellOverride-1 _idGenCellOverride-1" colspan="3">
							<p class="table-title"><span class="table-number">Table 8-7</span> Conditions Associated With Prominent Corneal Nerves</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">Enlarged Corneal Nerves</p>
						</td>
						<td class="Basic-Table CellOverride-2" />
						<td class="Basic-Table CellOverride-2">
							<p class="table-column-head">More Visible Corneal Nerves</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-34">
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Multiple endocrine neoplasia type 2B </p>
						</td>
						<td class="Basic-Table CellOverride-3" />
						<td class="Basic-Table CellOverride-3">
							<p class="table-body">Keratoconus</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Phytanic acid storage disease (Refsum syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Ichthyosis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Hansen disease (leprosy, beading of nerves) </p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Fuchs endothelial corneal dystrophy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Familial dysautonomia (Riley-Day syndrome)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Corneal edema</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-35">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Neurofibromatosis</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Congenital glaucoma</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body"><span class="CharOverride-3">Acanthamoeba</span> perineuritis</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">—</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer058">
				<div id="_idContainer056" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="BCSC2017-2018_S08_ch08_p173-204-web-resources/image/AAX-9351.png" alt="" />
				</div>
				<div id="_idContainer057" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-14"><span class="figure-number">Figure 8-16</span> Prominent corneal nerves. <span class="figure-source-note">(Courtesy of Robert&#160;W. Weisenthal, MD.)</span></p>
				</div>
			</div>
		</div>
	</body>
</html>
